CJC-1295 + Ipamorelin vs HGH: What the Research Shows
CJC-1295 + Ipamorelin and HGH side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider CJC-1295 + Ipamorelin if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
Consider HGH if…
- you want products with an FDA label: Genotropin (somatropin) is indicated for children with growth failure from inadequate growth hormone secretion[6]
- you want randomized data in adults with growth hormone deficiency: Within 3 months lean body mass rose 5.09% and body fat fell 10.89%; waist fell 1.42%.[13]
What they have in common
Spec comparison
Showing 8 of 11 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | CJC-1295 + Ipamorelin | HGH |
|---|---|---|
| Class | GHRH + GHRP blend | Recombinant growth hormone |
| Also called | CJC/Ipa | GH, growth hormone, generic HGH, IU |
| Category | Growth hormone | Growth hormone |
| FDA status | Not FDA approved · research blend | FDA approved (prescription only) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times. | Prohibited by WADA (S2.2.3)Growth hormone and its analogues and fragments are prohibited at all times (S2.2.3). |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 | 0.4 hours IV; 3.0 hours subcutaneousintravenous (normal adults); subcutaneous (GHD adults), Genotropin · FDA label (Genotropin) |
| Evidence strength | Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030 | Human RCT evidence, 4 of 4Strongest: Journal of applied physiology 2014, PMID 24235105 |
| Human studies we summarised | 6 human (3 randomized or controlled) of 19 summarised, across ingredients | 13 human (13 randomized or controlled) of 20 summarised |
| Typical study doses |
|
|
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
The blend has no trial of its own
No human trial cited here tested CJC-1295 and ipamorelin together. A recent review says product composition, dose and stacking practices are uncertain in unregulated supply chains.[14]
After a single injection of CJC-1295 in healthy adults, mean plasma IGF-I concentrations rose 1.5- to 3-fold for 9-11 days.[5]
In healthy male volunteers, ipamorelin produced a single episode of GH release that peaked at 0.67 hours and fell to negligible GH at every dose.[3]
What actual growth hormone has been tested for
Genotropin, a recombinant human growth hormone, is labelled for children with growth failure from conditions including growth hormone deficiency, Prader-Willi syndrome and Turner syndrome, and for adults with GH deficiency.[6]
A systematic review of trials in healthy, lean, physically fit young people found lean body mass rose by 2.1 kg on growth hormone, but strength and exercise capacity did not seem to improve.[15]
The same review found soft tissue edema and fatigue more often in growth hormone recipients than in controls.[15]
In a placebo-controlled trial in healthy, active young adults, neither the low nor the high GH dose changed maximum oxygen uptake.[12]
Genotropin's label gives a half-life of 3.0 hours after subcutaneous injection in adults with GH deficiency.[6]
Common questions
Is CJC-1295 with ipamorelin the same as HGH?
No. Growth hormone is an approved drug for specific conditions. A recent review notes the compounds sold for physique or performance use have no regulatory approval for those indications.[14]
Does HGH build muscle in healthy people?
In a systematic review of trials in fit young people, lean body mass rose but strength did not seem to improve.[15]
Is HGH an approved drug?
Yes, for specific conditions. Genotropin's label lists pediatric growth failure indications and adult GH deficiency.[6]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 3Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 4Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 6GENOTROPIN (SOMATROPIN) KIT [PFIZER LABORATORIES DIV PFIZER INC]FDA label (Genotropin), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 7Effect of growth hormone on aging connective tissue in muscle and tendon: gene expression, morphology, and function following immobilization and rehabilitation.Journal of applied physiology (Bethesda, Md. : 1985) · 2014PMID 24235105Accessed 2 Oct 2026
- 8Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin.European journal of endocrinology · 2013PMID 23447518Accessed 2 Oct 2026
- 9Local administration of growth hormone stimulates tendon collagen synthesis in elderly men.Journal of applied physiology (Bethesda, Md. : 1985) · 2012PMID 22961272Accessed 2 Oct 2026
- 10PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (somatropin[tiab] OR "recombinant human growth hormone"[tiab] OR "recombinant growth hormone"[tiab] OR rhGH[tiab] OR "growth hormone therapy"[tiab] OR "growth hormone treatment"[tiab] OR "growth hormone replacement"[tiab] OR "growth hormone administration"[tiab] OR "GH therapy"[tiab] OR "GH treatment"[tiab] OR "GH replacement"[tiab] OR "GH administration"[tiab] OR "growth hormone injection"[tiab] OR "growth hormone injections"[tiab] OR "growth hormone supplementation"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 12Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes.The Journal of clinical endocrinology and metabolism · 2005PMID 15784718Accessed 2 Oct 2026
- 13Two years of replacement therapy in adults with growth hormone deficiency.Clinical endocrinology · 1997PMID 9404448Accessed 2 Oct 2026
- 14The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 15Systematic review: the effects of growth hormone on athletic performance.Annals of internal medicine · 2008PMID 18347346Accessed 2 Oct 2026
Found an error? Report a correction.